Articles tagged "Rejection"

2017 American Transplant Congress
Liver Transplantation Outcomes Using Anti-Thymocyte Globulin Induction in Patients with Autoimmune Hepatitis.
S. LeCorchick, A. Sharma, I. Yakubu, C. Bhati, T. Reichman, L. Kang, M. Levy.
Transplantation Surgery, Virginia Commonwealth University, Richmond, VA
Background: The use of rabbit anti-thymocyte globulin (ATG) induction in high immunological risk patients with autoimmune hepatitis (AIH) could lower the rejection rates after liver…
2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
A. Vo, J. Choi, I. Kim, E. Huang, S. Louie, A. Kang, S. Williamson, K. Myers, A. Peng, R. Najjar, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…
2017 American Transplant Congress
Clinical Correlation of Endomyocardial Biopsies Molecular Profiling: Taking Rejection Diagnosis Beyond Histology.
L. Potena,¹ L. Borgese,¹ A. Gaudenzi,¹ V. Agostini,¹ J. Reeve,² M. Masetti,¹ F. Grigioni,¹ O. Leone,¹ P. Halloran.
¹University of Bologna, Bologna, Italy; ²Alberta Transplant Applied Genomics Centre, Edmonton, Canada
Histology grading of endomyocardial biopsies (EMB), the standard for diagnosing T-cell-mediated (TCMR) and antibody-mediated (ABMR) rejection, has serious issues with reproducibility (Transplantation 94 (11):1172177, 2012)…
2017 American Transplant Congress
Immunodominant Donor Specific Antibody Reduction with Proteasome Inhibitor Based Treatment: Clinical Variability and Implications for Long Term Graft Survival.
A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ A. Shields,² B. Abu Jawdeh,¹ B. Hardy,¹ M. Anand,¹ M. Cuffy,¹ M. Cardi,¹ R. Alloway,¹ E. Woodle.¹
¹University of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati
Proteasome inhibitor (PI) based regimens treat antibody mediated rejection (AMR) at least in part by eliminating donor specific antibody (DSA). iDSA response to PI-based therapy…
2017 American Transplant Congress
Pre-Transplant HLA-Specific B Cell Breadth of Reactivity in a Novel Multiplex Bead-Based Assay Predicts Rejection in Kidney Transplant Recipients.
Z. Ilyas,¹ A. Aki,¹ A. Tambur,¹ P. Heeger,² M. Ansari.¹
¹Northwestern University, Chicago; ²Icahn School of Medicine at Mount Sinai, New York
Introduction: Recipients with broad sensitization to HLA defined by a high percentage of Panel Reactive Antibodies (PRA) are at higher immunologic risk for poor graft…
2017 American Transplant Congress
Regulatory T Cells Inhibit Plasmablast Formation and IgG Production by Tempering T Follicular Helper Cell Function.
P. Fadakar, C. Macedo, M. Yamada, K. Hadi, D. Metes.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA
Background: Donor-specific antibodies (DSA) are an important biomarker for acute rejection, transplant glomerulopathy and late allograft failure in kidney transplantation. Few studies have characterized the…
2017 American Transplant Congress
Quantitative Gene Expression Analysis of CRM-Panel Genes Using FFPE Kidney Tissues for Transplant Injuries.
T. Sigdel, M. Nguyen, D. Dobi, S.-C. Hsieh, J. Liberto, F. Vincenti, M. Sarwal, Z. Laszik.
University of California San Francisco, San Francisco
Background: A common immune response module (CRM) of 11 genes was identified to define acute rejection (AR) through meta-analyses of 1030 different engrafted tissues including…
2017 American Transplant Congress
Mitochondrial Permeability Can Regulate Endothelial Cell Necroptosis and Promote Cardiac Allograft Rejection.
I. Gan,^1,2 J. Jiang,¹ D. Lian,¹ A. Jevnikar,^1,3 Z.-X. Zhang.^1,2
¹Matthew Mailing Centre for Translational Transplant Studies, Western University, London, ON, Canada; ²Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada; ³Department of Medicine, Western University, London, ON, Canada
Background: Transplant injury is invariably associated with programmed cell death (PCD) resulting in organ rejection. Many forms of PCD have been described including apoptosis, pyroptosis,…
2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
B.-H. Shin,¹ M. Everly,² J. Choi,¹ S. Ge,¹ A. Petrosyan,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Terasaki Foundation Laboratory, Los Angeles
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…
2017 American Transplant Congress
Pre-Operative Desensitization for Live Donor Liver Transplantation with Strong Donor-Specific Antibodies.
M. Fujiki,¹ K. Hashimoto,¹ A. Zhang,² F. Aucejo,¹ C. Quintini,¹ T. Diago,¹ B. Eghtesad,¹ C. Miller.¹
¹General Surgery, Cleveland Clinic, Cleveland, OH; ²Allogen Laboratories, Cleveland Clinic, Cleveland, OH
Background: Presence of strong donor-specific antibodies (DSA) (MFI>4000) likely results in uncomplicated short-term outcome in whole liver transplants due to absorption of DSA by the…